Since Dan O'Connor stepped in as CEO at Ambrx, its stock has rallied on the revival of a previously shelved anti-HER2 ADC. It also raised $78 million and completed its ATM offering. A former marine captain, O'Connor’s leadership is anything but militaristic, though his time served helped shape his style and approach to adverse conditions. On the Business of Biotech, we welcome Dan back to discuss the resurgence of Ambrx.
The successful use of artificial intelligence (AI) has been a long time coming. Today, more than 530 AI/ML-enabled medical devices have been authorized by the FDA. This article highlights some promising examples.